Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis

American Journal of Rhinology and Allergy

Volumn 23, Issue 5, 2009, Pages 512-517

  Bernstein, Jonathan A ^a   Prenner, Bruce ^b   Ferguson, Berrylin J ^c   Portnoy, Jay ^d   Wheeler, William J ^e   Sacks, Harry J ^e  

^a Bernstein Clinical Research Center   (United States)

^b Allergy Associates Medical Group Inc   (United States)

^c University of Pittsburgh School of Medicine   (United States)

^d CHILDREN S MERCY HOSPITAL   (United States)

^e Meda Pharmaceuticals Inc   (United States)

Author keywords

Antihistamine; Azelastine; Congestion; Efficacy; Nasal spray; Nasal symptoms; Quality of life; Reformulated; Seasonal allergic rhinitis

Indexed keywords

ASTEPRO; AZELASTINE; GENERIC DRUG; NOSE SPRAY; PLACEBO; SUCRALOSE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PHTHALAZINE DERIVATIVE; SUCROSE; SWEETENING AGENT; TRICHLOROSUCROSE;

ADOLESCENT; ADULT; AGED; ARTICLE; BITTER TASTE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TREATMENT FAILURE; EPISTAXIS; FEMALE; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; NASAL PRURITUS; NOSE CONGESTION; NOSE DISEASE; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SNEEZING; SOMNOLENCE; SWEETNESS; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; DRUG DESIGN; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; NOSE OBSTRUCTION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL OBSTRUCTION; PHTHALAZINES; RHINITIS, ALLERGIC, SEASONAL; SNEEZING; SUCROSE; SWEETENING AGENTS; TREATMENT OUTCOME;

EID: 70449713874     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2009.23.3396     Document Type: Article

References (24)

1. Bernstein JA. Azelastine hydrochloride: A review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin 23:2441-2452, 2007.
2. Casale TB. The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. J Allergy Clin Immunol 83:771-776, 1989.
3. Chand N, Pillar J, Nolan K, et al. Inhibition of allergic and nonallergic leukotriene C4 formation and histamine secretion by azelastine: Implication for its mechanism of action. Int Arch Allergy Appl Immunol 90:67-70, 1989.
4. Ito H, Nakamura Y, Takagi S, and Sakai K. Effects of azelastine on the level of serum interleukin-4 and soluble CD23 antigen in the treatment of nasal allergy. Arzneimittelforschung 48:1143-1147, 1998.
5. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity. J Allergy Clin Immunol 98:1088-1096, 1996.
6. Shinoda M, Watanabe N, Suko T, et al. Effects of antiallergic drugs on Substance P (SP) and vasoactive intestinal peptide (VIP) in nasal secretions. Am J Rhinol 11:237-241, 1997.
7. Nieber K, Baumgarten C, Rathsack R, et al. Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. Clin Exp Allergy 23:69-71, 1993.
8. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity. J Allergy Clin Immunol 98:1088-1096, 1996.
9. Inoue Y. Basic studies on antiallergy drug, 4-(p-chlorobenzyl)- 2[N-methylperhydroazepinyl-( 4)]-(2H)-phthalazinone hydrochloride (azelastine). Nichi Idaishi 50:65-72, 1983.
10. Banov CH, and Lieberman P. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol 86:28-35, 2001.
11. Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:74-81, 2008.
12. Patel P, D'Andrea C, and Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol 21:499-503, 2007.
13. Meda Pharmaceuticals. Astelin package insert. Somerset, NJ; Jan. 2009.
14. Berger WE. Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine nasal spray in patients with chronic rhinitis. Expert Opin Drug Metab Toxicol 5:91-102, 2009.
15. Juniper EF, and Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21:77-83, 1991.
16. Juniper EF, Guyatt GH, Griffith LE, and Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98:843-844, 1996.
17. Guidance for Industry. Allergic rhinitis: Clinical development programs for drug products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD, April 2000.
18. Lumry W, Prenner B, Corren J, et al. Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. Ann Allergy Asthma Immunol 99:267-272, 2007.
19. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial rhinitis with the French version of the SF-36 health status questionnaire. J Allergy Clin Immunol 94:182-188, 1994.
20. Juniper EF. Rhinitis management: The patient's perspective. Clin Exp Allergy 28:34-38, 1998.
21. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 99:S742-S749, 1997.
22. Corren J, Storms W, Bernstein J, et al., for the Azelastine Cetirizine Trail No. 1 (ACT 1) Study Group. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 27:543-553, 2005.
23. Berger W, Hampel F, Bernstein J, et al. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 97:375-381, 2006.
24. Wallace DV, and Dykewicz MS. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008.